Related Experiment Video
Updated: Dec 23, 2025
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Data analysis of PD-1 antibody in the treatment of melanoma patients
Ting Li1,2, Chao Zhang1,2, Gang Zhao3
1Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Abstract:
Data presented in this article are supplementary materials to the research article entitled "IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma". Data for melanoma patients who did not receive anti-PD-1 treatment were obtained from Tianjin Medical University Cancer Institute & Hospital from February 1981 to May 2013. Kaplan-Meier was used for survival analysis. RNA sequencing data from 28 melanoma patients receiving anti-PD-1 therapy were download from GEO database (GSE78220). Cluster analysis of RNA expression was performed using R (package pheatmap). The difference of PD-L1 expression was analysed by the Boxplot (R ggplot2 package). Differences between each group were analyzed by Fisher exact test. Information of 13 melanoma patients who had failed prior chemotherapy and treated in the Tianjin Medical University Cancer Institute & Hospital between July 2015 and December 2018 was collected. The response was captured by Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1).
Insights
Insulin-like growth factor-binding protein 2 (IGFBP2) influences programmed death-ligand 1 (PD-L1) expression in melanoma by activating the EGFR-STAT3 pathway. This finding offers new insights into melanoma treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Malignant melanoma is a significant health concern.
- Programmed death-ligand 1 (PD-L1) is a key immune checkpoint in cancer.
- Understanding regulatory pathways of PD-L1 is crucial for effective melanoma therapy.
Purpose of the Study:
- To investigate the role of Insulin-like growth factor-binding protein 2 (IGFBP2) in regulating PD-L1 expression in malignant melanoma.
- To elucidate the involvement of the Epidermal Growth Factor Receptor (EGFR)-Signal Transducer and Activator of Transcription 3 (STAT3) signaling pathway in this regulation.
Main Methods:
- Analysis of retrospective patient data from Tianjin Medical University Cancer Institute & Hospital.
- Kaplan-Meier survival analysis.
- RNA sequencing data from the Gene Expression Omnibus (GEO) database (GSE78220).
- Bioinformatic analysis including cluster analysis (R package pheatmap) and differential expression analysis (R ggplot2 package, Fisher exact test).
- Evaluation of treatment response using Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1).
Main Results:
- IGFBP2 was identified as a regulator of PD-L1 expression in melanoma.
- Activation of the EGFR-STAT3 signaling pathway by IGFBP2 was demonstrated to influence PD-L1 levels.
- Correlation between these molecular events and patient outcomes was explored.
Conclusions:
- IGFBP2 plays a critical role in modulating PD-L1 expression in malignant melanoma through the EGFR-STAT3 pathway.
- These findings provide a molecular basis for understanding melanoma progression and response to therapy.
- Targeting the IGFBP2-EGFR-STAT3-PD-L1 axis may represent a potential therapeutic strategy for melanoma.
More Related Videos
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023